Perspective Therapeutics (NYSE:CATX) Research Coverage Started at Truist Financial

Truist Financial initiated coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research report released on Wednesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $21.00 target price on the stock.

Several other equities research analysts also recently weighed in on the stock. Royal Bank of Canada reduced their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an outperform rating on the stock in a research note on Friday, August 16th. Oppenheimer dropped their target price on Perspective Therapeutics from $19.00 to $17.00 and set an outperform rating on the stock in a research report on Tuesday, August 13th. Bank of America initiated coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They issued a buy rating and a $24.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Perspective Therapeutics has a consensus rating of Buy and a consensus target price of $20.00.

Perspective Therapeutics Trading Up 2.5 %

Shares of Perspective Therapeutics stock opened at $12.57 on Wednesday. Perspective Therapeutics has a 52 week low of $2.20 and a 52 week high of $19.05. The firm has a 50-day simple moving average of $13.81.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. The company had revenue of $0.53 million during the quarter. On average, equities research analysts anticipate that Perspective Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Sykon Capital LLC grew its stake in Perspective Therapeutics by 4.7% in the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after acquiring an additional 1,717 shares during the period. Victory Capital Management Inc. purchased a new stake in Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd purchased a new stake in Perspective Therapeutics during the 2nd quarter worth approximately $118,000. The Manufacturers Life Insurance Company purchased a new position in shares of Perspective Therapeutics in the second quarter valued at approximately $188,000. Finally, ZWJ Investment Counsel Inc. purchased a new stake in shares of Perspective Therapeutics during the first quarter worth approximately $26,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.